https://www.selleckchem.com/pr....oducts/bay-k-8644.ht
However, much remains to be learned about its optimal usage in GCA and asubstantial minority of pa tients do not achieve sustained glucocorticoid-free remission. Numerous exciting new agents are under investigation to fill this treatment gap in GCA, with the GM-CSF inhibitor mavrilimumab, and IL-12/23 blockade with ustekinumab providing promise through targeting the GCA pathogenic pathway in its proximal portion.Introduction Dual antiplatelet therapy (DAPT) is standard treatment for patients with acute coronary syndrome (ACS). This i
Curtir
Comentario
Compartilhar
